Fairpointe Capital’s Charles River Laboratories CRL Stock Holding History

Fairpointe Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-214,129	Closed	-$15.1M	–	78
2015 Q2	$15.1M	Sell	214,129 -60,560	-22%	-$4.48M	0.21%	50
2015 Q1	$21.8M	Sell	274,689 -1,240,367	-82%	-$91.5M	0.29%	50
2014 Q4	$96.4M	Sell	1,515,056 -165,860	-10%	-$10.4M	1.27%	39
2014 Q3	$100M	Buy	1,680,916 +222	+0%	+$12.7K	1.34%	40
2014 Q2	$90M	Buy	1,680,694 +123,118	+8%	+$6.76M	1.2%	40
2014 Q1	$94M	Sell	1,557,576 -461,828	-23%	-$26.9M	1.28%	41
2013 Q4	$107M	Sell	2,019,404 -330,238	-14%	-$16.6M	1.56%	35
2013 Q3	$109M	Buy	2,349,642 +45,034	+2%	+$2.07M	1.83%	28
2013 Q2	$94.6M	Buy	+2,304,608	New	+$98.7M	1.9%	26

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fairpointe Capital's CRL Position: Q3 2015 in Review

Fairpointe Capital sold out of Charles River Laboratories (CRL) in Q3 2015, closing a stake of 214,129 shares — an estimated $15.1M sold.

Fairpointe Capital first reported a position in CRL in Q2 2013 and held it in 9 quarters. The position peaked at $109M in Q3 2013. 258 funds tracked by Wall St. Rank hold CRL as of Q3 2015.

Fairpointe Capital reported no remaining Charles River Laboratories position as of Q3 2015 after selling out during the quarter.
Fairpointe Capital sold 214,129 Charles River Laboratories shares in Q3 2015, an estimated $15.1M.
Fairpointe Capital first reported a position in Charles River Laboratories in Q2 2013 and held it in 9 quarters.
Fairpointe Capital's Charles River Laboratories position peaked at $109M in Q3 2013.
258 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2015.

Based on Fairpointe Capital's 13F filing for Q3 2015, filed 13 Nov 2015.